MAPT and tauopathy: After confirming the binding and conformational specificity of our selected nanobodies for recombinant tau fibrils, we next asked whether these nanobody-Fc fusion proteins selectively recognize tau aggregates formed in vivo in both a transgenic mouse model and human tauopathies.